Men's Health: Benign Prostatic Hyperplasia

Area of Science:

• Urology
• Men's Health
• Pharmacology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• BPH causes lower urinary tract symptoms (LUTS) due to urethral narrowing and gland innervation disruption.
• Risk factors include race, ethnicity, obesity, type 2 diabetes, alcohol, inactivity, and family history.

Purpose of the Study:

• To summarize current understanding and management strategies for BPH and LUTS.
• To outline diagnostic assessment using the American Urological Association Symptom Index (AUASI).
• To review pharmacologic treatments and indications for specialist consultation.

Main Methods:

• Review of existing literature and clinical guidelines for BPH management.
• Assessment of LUTS severity using the AUASI.
• Evaluation of pharmacologic interventions including alpha-blockers, 5-ARIs, anticholinergics, beta-3 agonists, and tadalafil.

Main Results:

• Watchful waiting is appropriate for mild LUTS.
• Alpha-1 adrenergic blockers are often first-line for severe symptoms, with combination therapy showing superior efficacy.
• Anticholinergics, beta-3 agonists, and tadalafil serve as second-line or adjunctive therapies for specific LUTS profiles.

Conclusions:

• Pharmacologic management of BPH-related LUTS involves a stepwise approach based on symptom severity and type.
• Combination therapy offers greater efficacy than monotherapy for moderate to severe symptoms.
• Consultation with urology specialists is crucial for refractory cases or complications such as recurrent UTIs or renal insufficiency.